La maladie de Parkinson en France (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Apomorphine-induced relief of the akinetic-rigid syndrome and early median nerve somatosensory evoked potentials (SEPs) in Parkinson's disease.

Identifieur interne : 001C71 ( Ncbi/Curation ); précédent : 001C70; suivant : 001C72

Apomorphine-induced relief of the akinetic-rigid syndrome and early median nerve somatosensory evoked potentials (SEPs) in Parkinson's disease.

Auteurs : F. Mauguière [France] ; E. Broussolle ; J. Isnard

Source :

RBID : pubmed:7688279

English descriptors

Abstract

Among early cortical median nerve SEPs the frontal N30 potential is known to show amplitude reduction during execution of voluntary movements and to be abnormally reduced in parkinsonian patients. However, it is not clear whether N30 abnormalities are related to the severity of motor disability in Parkinson's disease. To address this question we studied median nerve SEPs, using a 16-channel montage, in 7 patients chronically treated with subcutaneous (s.c.) injections of apomorphine hydrochloride for spontaneous "on-off" motor fluctuations. We observed no significant changes in the latency, amplitude or scalp topography of early SEPs when comparing traces and maps obtained in the "off" condition and during the "on" phase induced by s.c. injection of apomorphine. The absence of any SEP changes, despite a clear-cut relief of the akinetic-rigid syndrome, suggests that early cortical SEPs, and in particular the frontal N30 potential, at least when recorded in a subject at rest, are not usable as an objective means to assess the severity or the fluctuations of motor disability in Parkinson's disease.

PubMed: 7688279

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:7688279

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Apomorphine-induced relief of the akinetic-rigid syndrome and early median nerve somatosensory evoked potentials (SEPs) in Parkinson's disease.</title>
<author>
<name sortKey="Mauguiere, F" sort="Mauguiere, F" uniqKey="Mauguiere F" first="F" last="Mauguière">F. Mauguière</name>
<affiliation wicri:level="3">
<nlm:affiliation>Department of Functional Neurology and Epileptology, Hôpital Neurologique, Lyon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Functional Neurology and Epileptology, Hôpital Neurologique, Lyon</wicri:regionArea>
<placeName>
<region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Broussolle, E" sort="Broussolle, E" uniqKey="Broussolle E" first="E" last="Broussolle">E. Broussolle</name>
</author>
<author>
<name sortKey="Isnard, J" sort="Isnard, J" uniqKey="Isnard J" first="J" last="Isnard">J. Isnard</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="????">
<PubDate>
<MedlineDate>1993 Jul-Aug</MedlineDate>
</PubDate>
</date>
<idno type="RBID">pubmed:7688279</idno>
<idno type="pmid">7688279</idno>
<idno type="wicri:Area/PubMed/Corpus">001711</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001711</idno>
<idno type="wicri:Area/PubMed/Curation">001670</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001670</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001670</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001670</idno>
<idno type="wicri:Area/Ncbi/Merge">001C71</idno>
<idno type="wicri:Area/Ncbi/Curation">001C71</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Apomorphine-induced relief of the akinetic-rigid syndrome and early median nerve somatosensory evoked potentials (SEPs) in Parkinson's disease.</title>
<author>
<name sortKey="Mauguiere, F" sort="Mauguiere, F" uniqKey="Mauguiere F" first="F" last="Mauguière">F. Mauguière</name>
<affiliation wicri:level="3">
<nlm:affiliation>Department of Functional Neurology and Epileptology, Hôpital Neurologique, Lyon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Functional Neurology and Epileptology, Hôpital Neurologique, Lyon</wicri:regionArea>
<placeName>
<region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Broussolle, E" sort="Broussolle, E" uniqKey="Broussolle E" first="E" last="Broussolle">E. Broussolle</name>
</author>
<author>
<name sortKey="Isnard, J" sort="Isnard, J" uniqKey="Isnard J" first="J" last="Isnard">J. Isnard</name>
</author>
</analytic>
<series>
<title level="j">Electroencephalography and clinical neurophysiology</title>
<idno type="ISSN">0013-4694</idno>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Aged</term>
<term>Analysis of Variance</term>
<term>Apomorphine (therapeutic use)</term>
<term>Brain (physiopathology)</term>
<term>Brain Mapping</term>
<term>Electric Stimulation</term>
<term>Electroencephalography</term>
<term>Evoked Potentials, Somatosensory (physiology)</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Median Nerve (physiopathology)</term>
<term>Middle Aged</term>
<term>Movement Disorders (drug therapy)</term>
<term>Movement Disorders (etiology)</term>
<term>Movement Disorders (physiopathology)</term>
<term>Muscle Rigidity (drug therapy)</term>
<term>Muscle Rigidity (etiology)</term>
<term>Muscle Rigidity (physiopathology)</term>
<term>Parkinson Disease (complications)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Reaction Time (physiology)</term>
<term>Syndrome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Apomorphine</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en">
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Movement Disorders</term>
<term>Muscle Rigidity</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en">
<term>Movement Disorders</term>
<term>Muscle Rigidity</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en">
<term>Evoked Potentials, Somatosensory</term>
<term>Reaction Time</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en">
<term>Brain</term>
<term>Median Nerve</term>
<term>Movement Disorders</term>
<term>Muscle Rigidity</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Aged</term>
<term>Analysis of Variance</term>
<term>Brain Mapping</term>
<term>Electric Stimulation</term>
<term>Electroencephalography</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Syndrome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Among early cortical median nerve SEPs the frontal N30 potential is known to show amplitude reduction during execution of voluntary movements and to be abnormally reduced in parkinsonian patients. However, it is not clear whether N30 abnormalities are related to the severity of motor disability in Parkinson's disease. To address this question we studied median nerve SEPs, using a 16-channel montage, in 7 patients chronically treated with subcutaneous (s.c.) injections of apomorphine hydrochloride for spontaneous "on-off" motor fluctuations. We observed no significant changes in the latency, amplitude or scalp topography of early SEPs when comparing traces and maps obtained in the "off" condition and during the "on" phase induced by s.c. injection of apomorphine. The absence of any SEP changes, despite a clear-cut relief of the akinetic-rigid syndrome, suggests that early cortical SEPs, and in particular the frontal N30 potential, at least when recorded in a subject at rest, are not usable as an objective means to assess the severity or the fluctuations of motor disability in Parkinson's disease.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C71 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001C71 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Ncbi
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:7688279
   |texte=   Apomorphine-induced relief of the akinetic-rigid syndrome and early median nerve somatosensory evoked potentials (SEPs) in Parkinson's disease.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i   -Sk "pubmed:7688279" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonFranceV1 

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024